Saturday 17 October 2026
Export TCRT’s income statement to Excel — free account
Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
2.63
0.45
+20.64%
Follow TCRT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | — | — |
P/S ratio |
— | 449.52 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (11.40) | — | — | |
P/B ratio |
— | 2.92 | — | — | |
Price to Tangible BV |
— | 2.92 | — | — | |
EV/Sales |
— | 1,454.88 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (7.10) | — | — | |
EV/FCF |
— | (13.92) | — | — | |
Quick Ratio |
2.10 | 1.71 | 0.60 | 0.14 | |
Current Ratio |
2.92 | 2.45 | 1.63 | 0.77 | |
Net Debt/EBITDA |
1.63 | 1.53 | 0.35 | 0.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.62 | 1.02 | 0.32 | |
Capex/Depreciation |
0.00 | (0.14) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 12,066.67% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 18,266.67% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | (4,633.33%) | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.19 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (68.42%) | — | — | |
Free Cash Flow Yield |
— | (23.25%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.28) | (0.53) | (0.12) | |
Capex per Share |
(0.04) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.43) | (0.28) | (0.53) | (0.12) | |
Cash per Share |
0.89 | 0.71 | 0.18 | 0.05 | |
Shareholders Equity per Share |
1.28 | 1.11 | 0.66 | 0.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.28 | 1.11 | 0.66 | 0.27 | |
Free Cash Flow |
(0.94) | (0.55) | (1.03) | (0.30) | |
Working Capital |
1.76 | 1.18 | 0.38 | (0.20) | |
Capital Expenditures |
(0.10) | 0.00 | — | — | |
Net Current Asset Value |
1.76 | 1.18 | 0.38 | (0.20) | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.33 | — | — | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
— | 0.00 | — | — | |
Average Payables |
0.65 | 0.56 | 0.62 | 0.77 | |
Average Assets |
3.64 | 2.86 | 2.00 | 3.13 | |
Average Common Equity |
2.76 | 2.11 | 1.17 | 2.16 |
Columns are period end dates